Loading...

REMUS Remus Pharmaceuticals Ltd Major expansion or diversification plans Announcement

Rms

RMS

Remus Pharmaceuticals Ltd

(REMUS)

2025 Announcement

Analyst/Institutional Inves...

Geographic Expansion

Earnings Call Transcript

Postal Ballot Notice

Related Party Transaction

Conference Call Update

Investor Presentation

Q2 Earnings Report

Interim Dividend Declared

Financial Results Submitted

Earnings Call Scheduled

Capital Audit Disclosure

Email Address Change

Regulation Non-Applicability

SEBI Compliance Certificate

Trading Window Closure

AGM Voting Results

Annual General Meeting

Investor Meeting Scheduled

Newspaper Publication

Dividend Record Date

Annual General Meeting

Investor Meeting Scheduled

Board Meeting Outcome

Investor Presentation

Q1 Earnings Report

Analyst Meeting Scheduled

Subsidiary Incorporation

Regulation Exemption

Share Capital Audit

SEBI Certificate Submission

Bonus Shares Allotment

Bonus Shares Allotment

Disclosure Filing

Bonus Shares Record

Voting Results Passed

Postal Ballot Result

New Subsidiary Announced

New Subsidiary Formation

Earnings Call Transcript

Postal Ballot Notice

Bonus Issue Announcement

Earnings Call Recording

Investor Presentation

Financial Results Announced

Management Update

Management Change

Internal Auditor Appointment

Secretarial Auditor Appoint...

Bonus Issue Announced

Financial Results Released

Earnings Call Schedule

Compliance Certificate

RTA Contact Update

Regulation Non-Applicability

Capital Audit Submission

SEBI Certificate Submission

Trading Window Closure

Board Meeting Outcome

Registrar Change

RTA Name Change

Share Capital Audit

SEBI Certificate Update

Regulation Exemptions

Clarification on Results

Financial Results Submission

Investor Call Transcript

Investor Call Recording

Investor Presentation

Investors Call Scheduled

Financial Results

Financial Results Update

Financial Results

Regulation 32 Update

Submission Not Required

Financial Results

Strong Financial Results

Dividend Record Date

Regulation Exemption

SEBI Compliance Certificate

Trading Window Closure

AGM Voting Results

AGM Proceedings

Annual Report Dispatch

Annual General Meeting

Board Meeting Outcome

Regulation Non-Applicability

Certificate Submission

Bonus Equity Shares Approval

Bonus Allotment

Bonus Issue Approval

Disclosure Submission

Bonus Issue Record Date

EGM Proceedings

Non-applicability Announcement

Statement of Deviation

Pharmaceuticals Meeting Out...

EOGM Announcement

Bonus Issue Approval

Board Meeting Outcome

Bonus Issuance and Share Ca...

Dividend Announcement

Record Date Update

Dividend Record Date

SEBI Compliance Certificate...

Compliance Certificate Subm...

Regulation Non-Applicability

Certificate Submission

Trading Window Closure

Acquisition Completed

Newspaper Publication

Change in Auditors

Auditor Resignation

Board Meeting Outcome

Exemption from Corporate Go...

Certificate Submission

Subsidiary Incorporation

Subsidiary Incorporation

Deviation in Utilization of...

Non-Applicability of Regula...

Dividend Announcement

Financial Results, Dividend...

Non-Applicability of Regula...

Certificate Submission

Trading Window Closure

Management Disclosure

Annual Report Dispatch and ...

Closure of Register of Memb...

Dividend Record Date

Board Meeting outcome

External Links:

Data:

Remus Pharmaceuticals Limited announced the approval from its Board during a meeting on June 20, 2025, to incorporate a new subsidiary named Espee Global Clinical Trial Services Private Limited, aimed at providing clinical trial services, with an authorized share capital of ₹1 crore.

AI Assistant

Remus Pharmaceuticals Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.